EML4-ALK Fusion Transcripts Panel

  • Product Reviews (0)
  • Citations (4)

Research Focus

EML4-ALK fusion genes are present in about four percent of tumors from patients with non-small cell lung cancer (NSCLC). Investigations have shown that these rearranged genes promote tumor cell growth and predict lack of benefit from therapies that inhibit EGF receptor (EGFR) activity. Research investigation on ALK inhibitors have entered clinical development and first studies have shown efficacy in NSCLC patients harboring EML4-ALK fusion proteins.

Target Disease/Application

Lung Cancer / EGFR Therapy Biomarkers

Chromosomal Alteration


Assay ID Gene Symbol Gene Aliases Availability Amplicon Length  
Hs03654556_ft EML4-ALK ALK EML4 Made to Order 79
Hs03654557_ft EML4-ALK ALK EML4 Made to Order 86
Hs03654558_ft EML4-ALK ALK EML4 Made to Order 85
Hs03654559_ft EML4-ALK ALK EML4 Made to Order 80
Hs03654560_ft EML4-ALK ALK EML4 Made to Order 79


General Specifications

# of assays: 5
Technology: TaqMan® Assays - Pre-formulated assay (20x or 60x mix)
Scale: Available in multiple scales
Intended Use: Research Use Only

Kit Storage

-20° C


Product Literature


Citations & References (4)

Brian Dalby, Sharon Cates, Adam Harris, Elise C. Ohki, Mary L. Tilkins, Paul J. Price and Valentina
Others (2004) 33:95-103
Product Usage
Experimental variables involved in transfections with Lipofectamine 2000 were studied in this paper. Some of the cell lines transfected with plasmid DNA include 293-H, Cos-7L, CHO-S, MDCK and GripTite 293-MSR. Transfection of primary neurons, specifically E18 cortical neurons, and E18 hippocampal neurons is discussed. Cell lines transfected with siRNA were 293, BHK, CHO-K1, A549, and HeLa. Transfection protocols for high-throughput applications are also included.
Maria Paola Martelli et al.
The American Journal of Pathology, Vol. 174, No. 2, February 2009.
Jussi P. Koivunen et al.
Clin Cancer Res 4275 2008;14(13) July 1, 2008
Daisy Wing-Sze Wong, BSc et al.
Cancer. 2009 Apr 15;115(8):1723-33.